title: Update on the management of connective tissue malignancies.
abstract: Approximately 11,000 new cases of connective tissue malignancies are anticipated in 2004. These diseases can be divided into soft-tissue sarcomas, sarcomas of bone, and gastrointestinal stromal tumors. Optimal management of these diseases requires a multidisciplinary team with expertise in surgery, pathology, radiotherapy, and chemotherapy. Over half of patients with stage III soft tissue and bone sarcomas are cured, as are some patients with metastatic disease. Imatinib mesylate has been an important advance in the treatment of gastrointestinal stromal tumors.
authors.affiliation: Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Fanucchi
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000628:therapy; D003131:Combined Modality Therapy; D005770:Gastrointestinal Neoplasms / Q000628:therapy; D006801:Humans; D012509:Sarcoma / Q000628:therapy*; D012983:Soft Tissue Neoplasms / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents